Researchers have reported on the prolonged response to dual immune checkpoint blockade in patients with advanced solid tumors. The treatment has shown long-term survival gains in some patients, particularly those with non-small cell lung cancer, but it can also trigger immune-related adverse events. The effectiveness and potential drawbacks of immune checkpoint inhibitors are being explored in various studies, with some investigating combination therapies to overcome resistance and others examining the mechanisms of immune-related adverse events.